Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

ATXS

Phase 3

navenibart (STAR-0215)

Hereditary Angioedema

early 2027

ALPHA-ORBIT trial. 3/25/24- Reported initial POC results. 10/16/24- FDA & EMA orphan drug status. 12/11/24- Final results from target enrollment group. Present posters at AAAAI '25 on 3/2/25. 2/27/25- Initiated ALPHA-ORBIT Ph3 trial. Top-line results in early 2027.

Data readout

PROK

Phase 3

Rilparencel (REACT®

Stage 4 CKD caused by T2DM & late stage 3b w/ moderate to severe albuminuria

Q3 2027

REGEN-006 (PROACT 1) trial. 5/10/24- Completed and submitted protocol amendment in late Mar '24. Will resume enrollment. 9/3/24- To expedite enrollment and topline data readout to Q3 2027.

Data readout

PHAR

Phase 3

KL1333

Primary mitochondrial disease (PMD) w/ mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy)

2027

FALCON study. Acquired from Abliva AB. 3/13/25- Trial readout in 2027 w/ potential FDA approval by YE 2028.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20